JO2788B1 - Amido phenoxyendazole compounds beneficial as C-MET inhibitors - Google Patents

Amido phenoxyendazole compounds beneficial as C-MET inhibitors

Info

Publication number
JO2788B1
JO2788B1 JO2009256A JOP20090256A JO2788B1 JO 2788 B1 JO2788 B1 JO 2788B1 JO 2009256 A JO2009256 A JO 2009256A JO P20090256 A JOP20090256 A JO P20090256A JO 2788 B1 JO2788 B1 JO 2788B1
Authority
JO
Jordan
Prior art keywords
useful
amidophenoxyindazoles
inhibitors
met
cancer
Prior art date
Application number
JO2009256A
Other languages
Arabic (ar)
English (en)
Inventor
شيه شوان
زهونج بوي
اندرو بوبانز مارك
لاي تيشو
وو زهيبي
جينيفير يانج وي
Original Assignee
ايلي ليلي اند كومباني
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ايلي ليلي اند كومباني filed Critical ايلي ليلي اند كومباني
Application granted granted Critical
Publication of JO2788B1 publication Critical patent/JO2788B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
JO2009256A 2008-07-24 2009-07-12 Amido phenoxyendazole compounds beneficial as C-MET inhibitors JO2788B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8329408P 2008-07-24 2008-07-24
US8508208P 2008-07-31 2008-07-31
US10865908P 2008-10-27 2008-10-27

Publications (1)

Publication Number Publication Date
JO2788B1 true JO2788B1 (en) 2014-03-15

Family

ID=41010247

Family Applications (1)

Application Number Title Priority Date Filing Date
JO2009256A JO2788B1 (en) 2008-07-24 2009-07-12 Amido phenoxyendazole compounds beneficial as C-MET inhibitors

Country Status (35)

Country Link
US (2) US8030302B2 (enExample)
EP (1) EP2310382B1 (enExample)
JP (1) JP5414794B2 (enExample)
KR (1) KR101334456B1 (enExample)
CN (1) CN102105462B (enExample)
AR (1) AR074632A1 (enExample)
AT (1) ATE546444T1 (enExample)
AU (1) AU2009274256B2 (enExample)
BR (1) BRPI0916286B8 (enExample)
CA (1) CA2731773C (enExample)
CL (1) CL2011000134A1 (enExample)
CO (1) CO6351737A2 (enExample)
CR (1) CR20110046A (enExample)
CY (1) CY1112595T1 (enExample)
DK (1) DK2310382T3 (enExample)
DO (1) DOP2011000009A (enExample)
EA (1) EA018385B1 (enExample)
EC (1) ECSP11010778A (enExample)
ES (1) ES2379587T3 (enExample)
HR (1) HRP20120202T1 (enExample)
IL (1) IL210490A (enExample)
JO (1) JO2788B1 (enExample)
MA (1) MA32594B1 (enExample)
MX (1) MX2011000925A (enExample)
MY (1) MY163852A (enExample)
NZ (1) NZ590013A (enExample)
PE (1) PE20110150A1 (enExample)
PL (1) PL2310382T3 (enExample)
PT (1) PT2310382E (enExample)
RS (1) RS52261B (enExample)
SI (1) SI2310382T1 (enExample)
SV (1) SV2011003816A (enExample)
TW (1) TWI365185B (enExample)
WO (1) WO2010011538A1 (enExample)
ZA (1) ZA201100219B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293897B2 (en) 2008-10-14 2012-10-23 Ning Xi Compounds comprising a spiro-ring and methods of use
AU2010229147B2 (en) 2009-03-21 2012-07-05 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
ES2590778T3 (es) 2011-02-28 2016-11-23 Calitor Sciences, Llc Compuestos de quinolina sustituida
US8962623B2 (en) * 2011-03-04 2015-02-24 Locus Pharmaceuticals, Inc. Aminopyrazine compounds
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
EP2870178B1 (en) * 2012-05-09 2017-07-12 Eli Lilly and Company Anti-c-met antibodies
JP6433922B2 (ja) * 2013-02-27 2018-12-05 アレイ バイオファーマ、インコーポレイテッド インダゾール誘導体の調製に使用するための中間体およびその調製方法
CN104140393B (zh) * 2013-12-10 2016-09-21 郑州泰基鸿诺医药股份有限公司 一种芳环/芳杂环叔丁醇酯类化合物的制备方法
WO2015164161A1 (en) 2014-04-22 2015-10-29 Calitor Sciences, Llc Bicylcic pyrazolone compounds and methods of use
TW201716085A (zh) * 2015-08-12 2017-05-16 應克隆公司 癌症之組合療法
US20190336599A1 (en) * 2016-04-15 2019-11-07 Eli Lilly And Company Combination of ramucirumab and merestinib for use in treatment of colorectal cancer
EP3464380B1 (en) 2016-06-02 2024-11-06 Immunocore Limited Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein
CN109562282A (zh) * 2016-07-29 2019-04-02 伊莱利利公司 用于治疗癌症的使用merestinib和抗-pd-l1或抗-pd-1抑制剂的组合疗法
CN108069938A (zh) * 2016-11-15 2018-05-25 中国药科大学 2,4-二取代吡啶类化合物及其制备方法和应用
CN109982700A (zh) * 2016-11-16 2019-07-05 伊莱利利公司 具有外显子14跳跃突变或外显子14跳跃表型的癌症的治疗
EP3541383B1 (en) 2016-11-16 2021-01-06 Eli Lilly and Company Combination therapy for cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype
CN107382968A (zh) * 2017-07-06 2017-11-24 北京万全德众医药生物技术有限公司 一种吲哚类c‑Met抑制剂的制备方法
CN107311983A (zh) * 2017-07-06 2017-11-03 北京万全德众医药生物技术有限公司 吲哚类小分子c‑met抑制剂
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
EP3480201A1 (en) 2017-11-06 2019-05-08 Oncostellae, S.L. New analogs as androgen receptor and glucocorticoid receptor modulators
EP3719012B1 (en) 2017-11-24 2024-03-06 Medshine Discovery Inc. N-[4-[(2-amino-4-pyridinyl)oxy]-3-fluorophenyl]-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinecarboxamide derivatives as c-met/axl inhibitors for the treatment of tumors
US20210177828A1 (en) * 2018-01-17 2021-06-17 Nanjing Transthera Biosciences Co., Ltd. Tam family kinase /and csf1r kinase inhibitor and use thereof
AU2019237715B2 (en) 2018-03-08 2021-01-28 Wellmarker Bio Co., Ltd. Thienopyridine derivatives and pharmaceutical composition comprising same
EP3842425B1 (en) * 2018-08-24 2024-05-22 TransThera Sciences (Nanjing), Inc. Novel quinoline derivative inhibitor
CN112739691B (zh) * 2018-09-03 2023-05-23 泰励生物科技(上海)有限公司 用作抗癌药的trk抑制剂
CN112771053A (zh) 2019-09-06 2021-05-07 伟迈可生物有限公司 基于生物标志物的治疗组合物
CN117355533A (zh) * 2021-06-22 2024-01-05 株式会社Lg化学 作为蛋白激酶抑制剂的新型化合物
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO155316C (no) * 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
US5484681A (en) * 1994-10-31 1996-01-16 Xerox Corporation Conductive composite particles and processes for the preparation thereof
IL114149A0 (en) * 1995-06-14 1995-10-31 Yeda Res & Dev Modified avidin and streptavidin molecules and use thereof
US5747577A (en) * 1995-12-27 1998-05-05 Xerox Corporation Conductive particles containing carbon black and processes for the preparation thereof
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
US6964872B2 (en) * 2001-05-18 2005-11-15 Srl, Inc. Immunoassay method
US6956084B2 (en) * 2001-10-04 2005-10-18 Bridgestone Corporation Nano-particle preparation and applications
JP2004067703A (ja) * 2002-04-24 2004-03-04 Japan Science & Technology Corp 架橋ポリマー、微粒子および製造方法
US7192780B2 (en) * 2002-10-23 2007-03-20 Evident Technologies Fluorescent lifetime biological detection and imaging using water-stable semiconductor nanocrystals
JP4681451B2 (ja) 2002-10-28 2011-05-11 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Rho−キナーゼ阻害剤としてのヘテロアリールオキシ置換フェニルアミノピリミジン類
AU2004264038B2 (en) * 2003-07-17 2010-09-23 Life Technologies As Process for preparing coated magnetic particles
US7163998B2 (en) * 2003-09-09 2007-01-16 Eastman Kodak Company Stabilized polymer beads and method of preparation
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
EP1966214B9 (en) 2005-12-21 2017-09-13 Janssen Pharmaceutica N.V. Triazolopyridazines as tyrosine kinase modulators
WO2007103308A2 (en) * 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
EP2230264B1 (en) * 2006-06-29 2019-10-09 Life Technologies AS Particles containing multi-block polymers
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
DK2084162T3 (da) 2006-10-23 2012-10-01 Sgx Pharmaceuticals Inc Bicykliske triazoler som proteinkinasemodulatorer
JP5337799B2 (ja) 2007-06-27 2013-11-06 アーケマ・インコーポレイテッド ヒドロフルオロオレフィンの製造方法

Also Published As

Publication number Publication date
MY163852A (en) 2017-10-31
BRPI0916286B1 (pt) 2019-10-08
MX2011000925A (es) 2011-03-21
IL210490A (en) 2013-06-27
DK2310382T3 (da) 2012-03-26
EA018385B1 (ru) 2013-07-30
EP2310382A1 (en) 2011-04-20
CO6351737A2 (es) 2011-12-20
EA201170252A1 (ru) 2011-06-30
US8030302B2 (en) 2011-10-04
NZ590013A (en) 2012-06-29
KR20110022691A (ko) 2011-03-07
CN102105462A (zh) 2011-06-22
KR101334456B1 (ko) 2013-11-29
AU2009274256B2 (en) 2013-07-11
PT2310382E (pt) 2012-04-11
USRE43878E1 (en) 2012-12-25
PE20110150A1 (es) 2011-03-07
TWI365185B (en) 2012-06-01
CA2731773A1 (en) 2010-01-28
ECSP11010778A (es) 2011-02-28
PL2310382T3 (pl) 2012-07-31
SI2310382T1 (sl) 2012-04-30
BRPI0916286B8 (pt) 2021-05-25
JP2011529054A (ja) 2011-12-01
AU2009274256A1 (en) 2010-01-28
RS52261B (sr) 2012-10-31
AR074632A1 (es) 2011-02-02
CL2011000134A1 (es) 2011-07-08
TW201006817A (en) 2010-02-16
CY1112595T1 (el) 2016-02-10
ZA201100219B (en) 2012-06-27
US20100022529A1 (en) 2010-01-28
HK1155172A1 (en) 2012-05-11
WO2010011538A1 (en) 2010-01-28
SV2011003816A (es) 2011-03-17
DOP2011000009A (es) 2011-03-31
IL210490A0 (en) 2011-03-31
CN102105462B (zh) 2014-07-23
MA32594B1 (fr) 2011-09-01
CA2731773C (en) 2013-03-12
CR20110046A (es) 2011-04-27
ATE546444T1 (de) 2012-03-15
JP5414794B2 (ja) 2014-02-12
ES2379587T3 (es) 2012-04-27
HRP20120202T1 (hr) 2012-03-31
EP2310382B1 (en) 2012-02-22

Similar Documents

Publication Publication Date Title
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
EA201171367A1 (ru) Винилиндазолильные соединения
IN2012DN03883A (enExample)
IN2012DN00471A (enExample)
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
PT2303021T (pt) Compostos para tratamento do cancro
EA201170832A1 (ru) Пуриновые соединения
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
MX2009012228A (es) Compuesto de triazolil aminopirimidina.
EA200901074A1 (ru) Лечение метастатической стадии рака предстательной железы дегареликсом
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2013007268A (es) Activadores de pkm2 bicíclicos.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MY150600A (en) Use of opioid antagonists for treating urinary retention
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
MX2011006532A (es) Compuestos anticancerigenos.
AP2011005893A0 (en) Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer.
TN2011000013A1 (en) Amidophenoxyindazoles useful as inhibitors of c-met
UA101379C2 (en) Amidophenoxyindazoles useful in the treatment of cancer
CY1114071T1 (el) Ενωσεις βινυλοϊνδαζολυλιου
UA36194U (en) Use of quercetin as hepatoprotector
TN2011000545A1 (en) Vinyl indazolyl compounds
UA35660U (en) Use of antihomotoxic preparations as cytoprotectors